CA 19.9 Test
2,100 Kshs | Home Collection Available
Synonyms
Carbohydrate antigen 19.9, Pancreatic Cancer, Tumor Marker
Purpose
The CA 19.9 Test is a blood test that measures the level of carbohydrate antigen 19.9 (CA 19.9), a tumor marker primarily associated with pancreatic cancer. Elevated levels may also be found in other gastrointestinal cancers and some non-cancerous conditions.
CA 19.9 is a protein produced by certain types of cancer cells, particularly those in the pancreas, bile ducts, gallbladder, stomach, and colon. The test is not diagnostic on its own but serves as a monitoring and supportive tool in cancer care.
Other medical laboratory tests that can be performed alongside it include CEA, Liver Function Tests (LFTs), Amylase and Lipase Tests, CT scan, MRI, or abdominal ultrasound, Bilirubin test, Biopsy, and histopathology.
Together, these tests form a comprehensive diagnostic and monitoring approach for patients suspected of or being treated for pancreatic or gastrointestinal cancers.
Patient Preparation
The patient should avoid taking biotin supplements for at least 72 hours before sample collection.
Samples
1ml with a minimum volume of 0.7ml of serum collected in a red top tube or gel barrier tube. Transfer the separated serum to a plastic transport tube if a red-top tube is used. Store the sample at room temperature.
Reference Range
0-35units/ml
Results Turnaround
Within 24 hours of receipt of samples.
Diseases / Diagnostic indicators
Doctors primarily associate the CA 19.9 test with pancreatic cancer, but they may also detect elevated levels in liver, gastrointestinal (GI), and colorectal malignancies.
Here are some possible outcomes of the test;
- Elevated CA 19.9 Levels:
May indicate the presence of pancreatic cancer or other cancers such as bile duct, liver, stomach, or colorectal cancer. However, high levels can also occur in non-cancerous conditions, such as pancreatitis, liver cirrhosis, or bile duct obstruction.
- Normal CA 19.9 Levels:
Suggest that no cancer or inflammation is currently detectable at a level that raises this marker. However, early-stage cancers may not cause elevated CA 19.9, so a normal result does not always rule out cancer.
- Fluctuating or Declining Levels (in patients under treatment):
A decrease in CA 19.9 levels during or after treatment usually indicates that the therapy is working, whereas a rising trend may suggest treatment resistance, progression, or recurrence.
For more information on CA 19.9 testing, read this study.